Why the study?
Does pulmonary arterial hypertension screening improve outcomes in TBX4 mutation carriers?
Does pulmonary arterial hypertension screening improve outcomes in TBX4 mutation carriers?
Answers are grounded in this paper and cite their sources.
This article discusses the implementation of pulmonary arterial hypertension screening among TBX4 mutation carriers.
Extract Pulmonary arterial hypertension (PAH) is a rare disease characterized by progressive remodelling of the small pulmonary arteries, leading to right heart failure and death if left untreated. It is a form of precapillary pulmonary hypertension (PH) defined by right heart catheterization (RHC) as having a mean pulmonary arterial pressure (mPAP) >20 mmHg, pulmonary vascular resistance (PVR) >2 wood units (WU), and a pulmonary arterial wedge pressure (PAWP) ≤15 mmHg [1, 2].
No takes yet. Share an insight, caveat, or question.
Montani et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: